Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Th1 cytokines sensitize HER-expressing breast cancer cells to lapatinib.

Showalter LE, Oechsle C, Ghimirey N, Steele C, Czerniecki BJ, Koski GK.

PLoS One. 2019 Jan 18;14(1):e0210209. doi: 10.1371/journal.pone.0210209. eCollection 2019.

2.

The Shared Ethical Responsibility of Medically and Non-medically Qualified Experts in Human Drug Development Teams.

Kerpel-Fronius S, Becker S, Barrett J, Brun J, Carlesi R, Chan A, Collia LF, Dubois DJ, Kleist P, Koski G, Kurihara C, Laranjeira LF, Schenk J, Silva H.

Front Pharmacol. 2018 Sep 3;9:843. doi: 10.3389/fphar.2018.00843. eCollection 2018.

3.

Accreditation of Clinical Research Sites - Moving Forward.

Koski G, Kennedy L, Tobin MF, Whalen M.

N Engl J Med. 2018 Aug 2;379(5):405-407. doi: 10.1056/NEJMp1806934. Epub 2018 Jun 27. No abstract available.

PMID:
29949451
4.

LEAPS Vaccine Incorporating HER-2/neu Epitope Elicits Protection That Prevents and Limits Tumor Growth and Spread of Breast Cancer in a Mouse Model.

Rosenthal KS, Stone S, Koski G, Zimmerman DH.

J Immunol Res. 2017;2017:3613505. doi: 10.1155/2017/3613505. Epub 2017 Mar 26.

5.

Calcium mobilizing treatment acts as a co-signal for TLR-mediated induction of Interleukin-12 (IL-12p70) secretion by murine bone marrow-derived dendritic cells.

Huang E, Showalter L, Xu S, Czernliecki BJ, Koski GK.

Cell Immunol. 2017 Apr;314:26-35. doi: 10.1016/j.cellimm.2017.01.010. Epub 2017 Feb 1.

PMID:
28190517
6.

Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ERpos/HER2pos early breast cancer.

Lowenfeld L, Zaheer S, Oechsle C, Fracol M, Datta J, Xu S, Fitzpatrick E, Roses RE, Fisher CS, McDonald ES, Zhang PJ, DeMichele A, Mick R, Koski GK, Czerniecki BJ.

Oncoimmunology. 2016 Jul 1;6(9):e1207032. doi: 10.1080/2162402X.2016.1207032. eCollection 2017.

7.

Progressive loss of anti-HER2 CD4+ T-helper type 1 response in breast tumorigenesis and the potential for immune restoration.

Datta J, Rosemblit C, Berk E, Showalter L, Namjoshi P, Mick R, Lee KP, Brod AM, Yang RL, Kelz RR, Fitzpatrick E, Hoyt C, Feldman MD, Zhang PJ, Xu S, Koski GK, Czerniecki BJ.

Oncoimmunology. 2015 Apr 1;4(10):e1022301. eCollection 2015 Oct.

8.

Corrigendum: Core competencies for pharmaceutical physicians and drug development scientists.

Silva H, Stonier P, Buhler F, Deslypere JP, Criscuolo D, Nell G, Massud J, Geary S, Schenk J, Kerpel-Fronius S, Koski G, Clemens N, Klingmann I, Kesselring G, van Olden R, Dubois D.

Front Pharmacol. 2015 Jan 15;5:297. doi: 10.3389/fphar.2014.00297. eCollection 2014.

9.

The synergy of the whole: building a global system for clinical trials to accelerate medicines development.

Koski G, Tobin MF, Whalen M.

Clin Ther. 2014 Oct 1;36(10):1356-70. doi: 10.1016/j.clinthera.2014.09.006. Epub 2014 Oct 23.

PMID:
25444565
10.

The ethics and economics of pharmaceutical pricing.

Parker-Lue S, Santoro M, Koski G.

Annu Rev Pharmacol Toxicol. 2015;55:191-206. doi: 10.1146/annurev-pharmtox-010814-124649. Epub 2014 Aug 13. Review.

PMID:
25149920
11.

Core competencies for pharmaceutical physicians and drug development scientists.

Silva H, Stonier P, Buhler F, Deslypere JP, Criscuolo D, Nell G, Massud J, Geary S, Schenk J, Kerpel-Fronius S, Koski G, Clemens N, Klingmann I, Kesselring G, van Olden R, Dubois D.

Front Pharmacol. 2013 Aug 26;4:105. doi: 10.3389/fphar.2013.00105. eCollection 2013. Erratum in: Front Pharmacol. 2014;5:297.

12.

Extracellular ATP and Toll-like receptor 2 agonists trigger in human monocytes an activation program that favors T helper 17.

Paustian C, Taylor P, Johnson T, Xu M, Ramirez N, Rosenthal KS, Shu S, Cohen PA, Czerniecki BJ, Koski GK.

PLoS One. 2013;8(1):e54804. doi: 10.1371/journal.pone.0054804. Epub 2013 Jan 31.

13.

HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ.

Sharma A, Koldovsky U, Xu S, Mick R, Roses R, Fitzpatrick E, Weinstein S, Nisenbaum H, Levine BL, Fox K, Zhang P, Koski G, Czerniecki BJ.

Cancer. 2012 Sep 1;118(17):4354-62. doi: 10.1002/cncr.26734. Epub 2012 Jan 17.

14.

A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer.

Koski GK, Koldovsky U, Xu S, Mick R, Sharma A, Fitzpatrick E, Weinstein S, Nisenbaum H, Levine BL, Fox K, Zhang P, Czerniecki BJ.

J Immunother. 2012 Jan;35(1):54-65. doi: 10.1097/CJI.0b013e318235f512.

15.

A national registry for healthy volunteers in phase 1 clinical trials.

Resnik DB, Koski G.

JAMA. 2011 Mar 23;305(12):1236-7. doi: 10.1001/jama.2011.354. Epub 2011 Mar 15. No abstract available.

16.

Comment on "Multidimensional results reporting to participants in genomic studies: getting it right".

Bookman EB, Langehorne AA, Eckfeldt JH, Glass KC, Jarvik GP, Klag M, Koski G, Motulsky A, Wilfond B, Manolio TA, Fabsitz RR, Luepker RV.

Sci Transl Med. 2011 Feb 16;3(70):70le1. doi: 10.1126/scitranslmed.3001516.

17.

Effect of multiple activation stimuli on the generation of Th1-polarizing dendritic cells.

Paustian C, Caspell R, Johnson T, Cohen PA, Shu S, Xu S, Czerniecki BJ, Koski GK.

Hum Immunol. 2011 Jan;72(1):24-31. doi: 10.1016/j.humimm.2010.10.004. Epub 2010 Oct 15.

PMID:
20951755
18.

"Rethinking research ethics," again: Casuistry, phronesis, and the continuing challenges of human research.

Koski G.

Am J Bioeth. 2010 Oct;10(10):37-9. doi: 10.1080/15265161.2010.526444. No abstract available.

PMID:
20945265
19.

J-LEAPS vaccines initiate murine Th1 responses by activating dendritic cells.

Taylor PR, Koski GK, Paustian CC, Bailey E, Cohen PA, Moore FB, Zimmerman DH, Rosenthal KS.

Vaccine. 2010 Aug 2;28(34):5533-42. doi: 10.1016/j.vaccine.2010.06.043. Epub 2010 Jun 25.

PMID:
20600501
20.

Consent for genetic research in the Framingham Heart Study.

Levy D, Splansky GL, Strand NK, Atwood LD, Benjamin EJ, Blease S, Cupples LA, D'Agostino RB Sr, Fox CS, Kelly-Hayes M, Koski G, Larson MG, Mutalik KM, Oberacker E, O'Donnell CJ, Sutherland P, Valentino M, Vasan RS, Wolf PA, Murabito JM.

Am J Med Genet A. 2010 May;152A(5):1250-6. doi: 10.1002/ajmg.a.33377.

21.

Maturation of dendritic cell precursors into IL12-producing DCs by J-LEAPS immunogens.

Taylor PR, Paustian CC, Koski GK, Zimmerman DH, Rosenthal KS.

Cell Immunol. 2010;262(1):1-5. doi: 10.1016/j.cellimm.2010.01.003. Epub 2010 Feb 1.

22.

Immunotherapy using allogeneic squamous cell tumor-dendritic cell fusion hybrids.

Lee WT, Tan C, Koski G, Shu S, Cohen P.

Head Neck. 2010 Sep;32(9):1209-16. doi: 10.1002/hed.21323.

PMID:
20054852
23.

Toll-like receptor agonists as third signals for dendritic cell-tumor fusion vaccines.

Cho EI, Tan C, Koski GK, Cohen PA, Shu S, Lee WT.

Head Neck. 2010 Jun;32(6):700-7. doi: 10.1002/hed.21241.

PMID:
19908319
24.

Opinions of IRB Members and Chairs Regarding Investigators' Relationships with Industry.

Weissman JS, Koski G, Vogeli C, Thiessen C, Campbell EG.

J Empir Res Hum Res Ethics. 2008 Mar;3(1):3-13. doi: 10.1525/jer.2008.3.1.3.

PMID:
19385778
25.

Policies and management of conflicts of interest within medical research institutional review boards: results of a national study.

Vogeli C, Koski G, Campbell EG.

Acad Med. 2009 Apr;84(4):488-94. doi: 10.1097/ACM.0b013e31819a8ae7.

26.

Subjects' views of obligations to ensure post-trial access to drugs, care and information: qualitative results from the Experiences of Participants in Clinical Trials (EPIC) study.

Sofaer N, Thiessen C, Goold SD, Ballou J, Getz KA, Koski G, Krueger RA, Weissman JS.

J Med Ethics. 2009 Mar;35(3):183-8. doi: 10.1136/jme.2008.024711.

27.

Differential production of IL-23 and IL-12 by myeloid-derived dendritic cells in response to TLR agonists.

Roses RE, Xu S, Xu M, Koldovsky U, Koski G, Czerniecki BJ.

J Immunol. 2008 Oct 1;181(7):5120-7.

28.

STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells.

Cohen PA, Koski GK, Czerniecki BJ, Bunting KD, Fu XY, Wang Z, Zhang WJ, Carter CS, Awad M, Distel CA, Nagem H, Paustian CC, Johnson TD, Tisdale JF, Shu S.

Blood. 2008 Sep 1;112(5):1832-43. doi: 10.1182/blood-2007-12-130138. Epub 2008 Jun 24.

29.

Paired Toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12.

Zheng R, Cohen PA, Paustian CA, Johnson TD, Lee WT, Shu S, Koski GK.

Cancer Res. 2008 Jun 1;68(11):4045-9. doi: 10.1158/0008-5472.CAN-07-6669.

30.

Tipping point, over the top, or just noncompliance as usual?

Koski G.

Hastings Cent Rep. 2008 Mar-Apr;38(2):27-9. No abstract available.

PMID:
18457226
31.

Reengineering dendritic cell-based anti-cancer vaccines.

Koski GK, Cohen PA, Roses RE, Xu S, Czerniecki BJ.

Immunol Rev. 2008 Apr;222:256-76. doi: 10.1111/j.1600-065X.2008.00617.x. Review.

PMID:
18364007
32.

Effective treatment of spontaneous metastases derived from a poorly immunogenic murine mammary carcinoma by combined dendritic-tumor hybrid vaccination and adoptive transfer of sensitized T cells.

Tamai H, Watanabe S, Zheng R, Deguchi K, Cohen PA, Koski GK, Shu S.

Clin Immunol. 2008 Apr;127(1):66-77. doi: 10.1016/j.clim.2007.12.001. Epub 2008 Feb 11.

PMID:
18262845
33.

Radiation therapy and Toll-like receptor signaling: implications for the treatment of cancer.

Roses RE, Xu M, Koski GK, Czerniecki BJ.

Oncogene. 2008 Jan 7;27(2):200-7. doi: 10.1038/sj.onc.1210909. Review.

PMID:
18176601
34.

Development of vaccines for high-risk ductal carcinoma in situ of the breast.

Czerniecki BJ, Roses RE, Koski GK.

Cancer Res. 2007 Jul 15;67(14):6531-4. Review.

35.

The clinical research process: building a system in harmony with its users.

Koski G.

Cancer Treat Res. 2007;132:275-90. Review. No abstract available.

PMID:
17305028
36.

Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion.

Czerniecki BJ, Koski GK, Koldovsky U, Xu S, Cohen PA, Mick R, Nisenbaum H, Pasha T, Xu M, Fox KR, Weinstein S, Orel SG, Vonderheide R, Coukos G, DeMichele A, Araujo L, Spitz FR, Rosen M, Levine BL, June C, Zhang PJ.

Cancer Res. 2007 Feb 15;67(4):1842-52. Epub 2007 Feb 9.

37.

Financial relationships between institutional review board members and industry.

Campbell EG, Weissman JS, Vogeli C, Clarridge BR, Abraham M, Marder JE, Koski G.

N Engl J Med. 2006 Nov 30;355(22):2321-9.

38.

High-avidity antitumor T-cell generation by toll receptor 8-primed, myeloid- derived dendritic cells is mediated by IL-12 production.

Xu S, Koldovsky U, Xu M, Wang D, Fitzpatrick E, Son G, Koski G, Czerniecki BJ.

Surgery. 2006 Aug;140(2):170-8.

PMID:
16904966
39.

Reporting genetic results in research studies: summary and recommendations of an NHLBI working group.

Bookman EB, Langehorne AA, Eckfeldt JH, Glass KC, Jarvik GP, Klag M, Koski G, Motulsky A, Wilfond B, Manolio TA, Fabsitz RR, Luepker RV; NHLBI Working Group.

Am J Med Genet A. 2006 May 15;140(10):1033-40.

40.

Cooperative research ethics review boards: a win-win solution?

Koski G, Aungst J, Kupersmith J, Getz K, Rimoin D.

IRB. 2005 May-Jun;27(3):1-7. No abstract available.

PMID:
16021793
41.

Combining innate immunity with radiation therapy for cancer treatment.

Koski GK, Czerniecki BJ.

Clin Cancer Res. 2005 Jan 1;11(1):7-11. Review. No abstract available.

42.

Research, regulations, and responsibility: confronting the compliance myth--a reaction to Professor Gatter.

Koski G.

Emory Law J. 2003 Winter;52(1):403-16. No abstract available.

PMID:
15575097
43.

FDA and the life-sciences industry: business as usual?

Koski G.

Hastings Cent Rep. 2004 Sep-Oct;34(5):24-7. No abstract available.

PMID:
15553395
44.

Ethics, science, and oversight of critical care research: the Office for Human Research Protections.

Koski G.

Am J Respir Crit Care Med. 2004 May 1;169(9):982-6. Review. No abstract available.

PMID:
15107303
45.

Drug-testing research in high school students: is there a will or a way?

Koski G.

Am J Bioeth. 2004 Winter;4(1):33-5. No abstract available.

PMID:
15035941
46.
47.

Beyond compliance...is it too much to ask?

Koski G.

IRB. 2003 Sep-Oct;25(5):5-6. No abstract available.

PMID:
14870726
48.

Changing the paradigm: new directions in federal oversight of human research.

Koski G.

J Pediatr Gastroenterol Nutr. 2003 Nov-Dec;37 Suppl 1:S2-6.

PMID:
14685070
49.

Imagination and attention: protecting participants in psychopharmacological research.

Koski G.

Psychopharmacology (Berl). 2003 Dec;171(1):56-7. Epub 2003 Nov 4. No abstract available.

PMID:
14598015
50.

Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients.

Bedrosian I, Mick R, Xu S, Nisenbaum H, Faries M, Zhang P, Cohen PA, Koski G, Czerniecki BJ.

J Clin Oncol. 2003 Oct 15;21(20):3826-35.

PMID:
14551301

Supplemental Content

Support Center